Regulation of protein prenylation.

[1]  S. Holstein,et al.  Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target , 2023, Clinical and translational medicine.

[2]  Ozge Sensoy,et al.  Mechanistic insight into impact of phosphorylation on the enzymatic steps of farnesyltransferase , 2022, Protein science : a publication of the Protein Society.

[3]  E. Pankratova,et al.  Suppression of OCT-1 in Metastatic Breast Cancer Cells Reduces Tumor Metastatic Potential, Hypoxia Resistance, and Drug Resistance , 2022, Life.

[4]  Liang Yan,et al.  How zoledronic acid improves osteoporosis by acting on osteoclasts , 2022, Frontiers in Pharmacology.

[5]  P. Lansbury,et al.  Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice , 2022, Molecular neurodegeneration.

[6]  M. Distefano,et al.  In vivo prenylomic profiling in the brain of a transgenic mouse model of Alzheimer’s disease reveals increased prenylation of a key set of proteins , 2022, bioRxiv.

[7]  T. Coenye,et al.  The anti-virulence activity of the non-mevalonate pathway inhibitor FR900098 towards Burkholderia cenocepacia is maintained during experimental evolution. , 2022, Microbiology.

[8]  Patrick Stelmach,et al.  Characterization of the promoter of the human farnesyltransferase beta subunit and the impact of the transcription factor OCT-1 on its expression. , 2022, Genomics.

[9]  C. Thomssen,et al.  FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer , 2022, Cancers.

[10]  Wei Wei,et al.  Overcoming chemoresistance in glioblastoma by fluvastatin via prenylation-dependent inhibition of Ras signaling , 2022, Human & experimental toxicology.

[11]  I. Jialal,et al.  Bempedoic acid: a novel oral LDL-cholesterol lowering agent. , 2022, International journal of physiology, pathophysiology and pharmacology.

[12]  A. Ehrhardt,et al.  Bacteria Are New Targets for Inhibitors of Human Farnesyltransferase , 2021, Frontiers in Microbiology.

[13]  M. Kumar,et al.  PARIS farnesylation prevents neurodegeneration in models of Parkinson’s disease , 2021, Science Translational Medicine.

[14]  Y. Cho,et al.  Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer , 2021, Journal for ImmunoTherapy of Cancer.

[15]  Carol L. Williams,et al.  SmgGDS: An Emerging Master Regulator of Prenylation and Trafficking by Small GTPases in the Ras and Rho Families , 2021, Frontiers in Molecular Biosciences.

[16]  D. Bennett,et al.  Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice , 2021, Acta Neuropathologica Communications.

[17]  C. Ballantyne,et al.  Role of Bempedoic Acid in Clinical Practice , 2021, Cardiovascular Drugs and Therapy.

[18]  H. Bachmann,et al.  Molecular and Pharmacological Characterization of the Interaction between Human Geranylgeranyltransferase Type I and Ras-Related Protein Rap1B , 2021, International journal of molecular sciences.

[19]  Sohita Dhillon.  Lonafarnib: First Approval , 2021, Drugs.

[20]  B. Turk,et al.  Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association , 2020, Proceedings of the National Academy of Sciences.

[21]  N. Elvassore,et al.  Nuclear Morphological Remodeling in Human Granulocytes Is Linked to Prenylation Independently from Cytoskeleton , 2020, Cells.

[22]  Danfang Yu,et al.  Atorvastatin disrupts primary human brain microvascular endothelial cell functions via prenylation‐dependent mitochondrial inhibition and oxidative stress , 2020, Fundamental & clinical pharmacology.

[23]  Chung-Jen Chen,et al.  Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout , 2020, International journal of molecular sciences.

[24]  R. Kuruvilla,et al.  Prenylation of Axonally Translated Rac1 Controls NGF-Dependent Axon Growth. , 2020, Developmental cell.

[25]  A. Markham.  Bempedoic Acid: First Approval , 2020, Drugs.

[26]  M. Ikura,et al.  A Non-Canonical Calmodulin Target Motif Comprising a Polybasic Region and Lipidated Terminal Residue Regulates Localization , 2020, International journal of molecular sciences.

[27]  M. Ikura,et al.  Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety , 2020, Science Signaling.

[28]  H. Masumoto,et al.  A SNARE geranylgeranyltransferase essential for the organization of the Golgi apparatus , 2020, The EMBO journal.

[29]  James L. Hougland,et al.  Protein farnesyltransferase catalyzes unanticipated farnesylation and geranylgeranylation of shortened target sequences. , 2020, Biochemistry.

[30]  S. Yeh,et al.  Androgen receptor‐regulated circFNTA activates KRAS signaling to promote bladder cancer invasion , 2020, EMBO reports.

[31]  Carol L. Williams,et al.  Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy , 2020, Proceedings of the National Academy of Sciences.

[32]  Tao Wang,et al.  Re-recognition of pseudogenes: From molecular to clinical applications , 2020, Theranostics.

[33]  Huaiyuan Guo,et al.  circ-FNTA accelerates proliferation and invasion of bladder cancer , 2019, Oncology letters.

[34]  Chaoqun Ma,et al.  Rce1 suppresses invasion and metastasis of hepatocellular carcinoma via epithelial‐mesenchymal transition induced by the TGF‐β1/H‐Ras signaling pathway , 2020, Journal of cellular physiology.

[35]  P. Lansbury,et al.  Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by α-Synuclein , 2019, Neuron.

[36]  C. Fierke,et al.  The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases , 2019, The Journal of Biological Chemistry.

[37]  M. Pagano,et al.  GGTase3 is a Newly Identified Geranylgeranyltransferase Targeting a Ubiquitin Ligase , 2019, Nature Structural & Molecular Biology.

[38]  John W M Martens,et al.  MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines , 2019, PloS one.

[39]  L. Schoofs,et al.  Flip-Flopping Retinal in Microbial Rhodopsins as a Template for a Farnesyl/Prenyl Flip-Flop Model in Eukaryote GPCRs , 2019, Front. Neurosci..

[40]  M. Glogauer,et al.  Control of antiviral innate immune response by protein geranylgeranylation , 2019, Science Advances.

[41]  S. Haggarty,et al.  A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy , 2019, Science Translational Medicine.

[42]  B. Wojciak-Stothard,et al.  Dual Chemical Probes Enable Quantitative System-Wide Analysis of Protein Prenylation and Prenylation Dynamics , 2019, Nature Chemistry.

[43]  A. Pant,et al.  Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells , 2019, Toxicology and applied pharmacology.

[44]  S. Bicciato,et al.  Isoprenylcysteine carboxy methyltransferase (ICMT) is associated with tumor aggressiveness and its expression is controlled by the p53 tumor suppressor , 2019, The Journal of Biological Chemistry.

[45]  B. Wan,et al.  Inhibition of GGPPS1 attenuated LPS-induced acute lung injury and was associated with NLRP3 inflammasome suppression. , 2019, American journal of physiology. Lung cellular and molecular physiology.

[46]  M. D. Fullerton,et al.  Does prenylation predict progression in NAFLD? , 2018, The Journal of pathology.

[47]  Sophie Mockly,et al.  Inconsistencies and Limitations of Current MicroRNA Target Identification Methods. , 2019, Methods in molecular biology.

[48]  James L. Hougland,et al.  Protein Isoprenylation in Yeast Targets COOH-Terminal Sequences Not Adhering to the CaaX Consensus , 2018, Genetics.

[49]  Yitao Ding,et al.  Geranylgeranyl diphosphate synthase (GGPPS) regulates non‐alcoholic fatty liver disease (NAFLD)–fibrosis progression by determining hepatic glucose/fatty acid preference under high‐fat diet conditions , 2018, The Journal of pathology.

[50]  A. Berghuis,et al.  Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors. , 2018, Journal of medicinal chemistry.

[51]  C. Loganes,et al.  Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice. , 2018, Current medicinal chemistry.

[52]  C. Fierke,et al.  SmgGDS-607 Regulation of RhoA GTPase Prenylation Is Nucleotide-Dependent. , 2018, Biochemistry.

[53]  P. Farci,et al.  Current and Future Management of Chronic Hepatitis D. , 2018, Gastroenterology & hepatology.

[54]  M. Distefano,et al.  Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease , 2018, Critical reviews in biochemistry and molecular biology.

[55]  R. D'Agostino,et al.  Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome , 2018, JAMA.

[56]  M. Buck,et al.  Cyclase-associated protein 1 (CAP1) is a prenyl-binding partner of Rap1 GTPase , 2018, The Journal of Biological Chemistry.

[57]  T. M. Dore,et al.  Rce1: mechanism and inhibition , 2018, Critical reviews in biochemistry and molecular biology.

[58]  Daniele M. Gilkes,et al.  RhoB: Team Oncogene or Team Tumor Suppressor? , 2018, Genes.

[59]  Qingqing Zhu,et al.  Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma , 2018, Journal of cellular and molecular medicine.

[60]  James L. Hougland,et al.  Efficient farnesylation of an extended C-terminal C(x)3X sequence motif expands the scope of the prenylated proteome , 2017, The Journal of Biological Chemistry.

[61]  I. Manthey,et al.  Exploring the putative self‐binding property of the human farnesyltransferase alpha‐subunit , 2017, FEBS letters.

[62]  F. Eisenhaber,et al.  Prenylation of viral proteins by enzymes of the host: Virus‐driven rationale for therapy with statins and FT/GGT1 inhibitors , 2017, BioEssays : news and reviews in molecular, cellular and developmental biology.

[63]  Wei Wei,et al.  Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling. , 2017, Biochemical and biophysical research communications.

[64]  F. Drijfhout,et al.  Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer , 2017, Scientific Reports.

[65]  D. Kambach,et al.  Viral MicroRNAs Repress the Cholesterol Pathway, and 25-Hydroxycholesterol Inhibits Infection , 2017, mBio.

[66]  C. Herrmann,et al.  Nucleotide-dependent farnesyl switch orchestrates polymerization and membrane binding of human guanylate-binding protein 1 , 2017, Proceedings of the National Academy of Sciences.

[67]  G. L. Hamilton,et al.  Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. , 2017, ACS chemical biology.

[68]  Kyung-Hee Kim,et al.  Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents , 2017, Amino Acids.

[69]  Jin Huang,et al.  New tricks for human farnesyltransferase inhibitor: cancer and beyond. , 2017, MedChemComm.

[70]  U. Laufs,et al.  Pleiotropic Effects of Statins on the Cardiovascular System , 2017, Circulation research.

[71]  J. Mitchell,et al.  Tipifarnib prevents development of hypoxia-induced pulmonary hypertension , 2017, Cardiovascular research.

[72]  Carol L. Williams,et al.  Differences in the Phosphorylation-Dependent Regulation of Prenylation of Rap1A and Rap1B. , 2016, Journal of molecular biology.

[73]  L. Wells,et al.  A shunt pathway limits the CaaX processing of Hsp40 Ydj1p and regulates Ydj1p-dependent phenotypes , 2016, eLife.

[74]  Yong Zhou,et al.  VPS35 binds farnesylated N-Ras in the cytosol to regulate N-Ras trafficking , 2016, The Journal of cell biology.

[75]  G. Landreth,et al.  Simvastatin inhibits protein isoprenylation in the brain , 2016, Neuroscience.

[76]  P. Bastiaens,et al.  Identification of pyrazolopyridazinones as PDEδ inhibitors , 2016, Nature Communications.

[77]  J. Pereira-Leal,et al.  Are There Rab GTPases in Archaea? , 2016, Molecular biology and evolution.

[78]  P. Casey,et al.  Protein prenylation: unique fats make their mark on biology , 2016, Nature Reviews Molecular Cell Biology.

[79]  S. Miyata,et al.  Statins up-regulate SmgGDS through β1-integrin/Akt1 pathway in endothelial cells. , 2016, Cardiovascular research.

[80]  Guillermo A. Gomez,et al.  Mammalian farnesyltransferase α subunit regulates vacuolar protein sorting-associated protein 4A (Vps4A)--dependent intracellular trafficking through recycling endosomes. , 2015, Biochemical and biophysical research communications.

[81]  A. Kowluru,et al.  Protein prenylation in islet β-cell function in health and diabetes: Putting the pieces of the puzzle together. , 2015, Biochemical pharmacology.

[82]  Q. Zeng,et al.  Arabidopsis Rab Geranylgeranyltransferases Demonstrate Redundancy and Broad Substrate Specificity in Vitro* , 2015, The Journal of Biological Chemistry.

[83]  P. Hillemanns,et al.  The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. , 2015, British journal of clinical pharmacology.

[84]  Laetitia Canini,et al.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. , 2015, The Lancet. Infectious diseases.

[85]  T. Elston,et al.  Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases* , 2015, The Journal of Biological Chemistry.

[86]  Guangchuang Yu,et al.  ACK1 promotes gastric cancer epithelial–mesenchymal transition and metastasis through AKT–POU2F1–ECD signalling , 2015, The Journal of pathology.

[87]  Na Xu,et al.  Protein prenylation and human diseases: a balance of protein farnesylation and geranylgeranylation , 2015, Science China Life Sciences.

[88]  Malte Schmick,et al.  Ras moves to stay in place. , 2015, Trends in cell biology.

[89]  Youyong Li,et al.  Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling. , 2015, Drug discovery today.

[90]  M. Distefano,et al.  Protein Prenylation: Enzymes, Therapeutics, and Biotechnology Applications , 2014, ACS chemical biology.

[91]  S. C. Flynn,et al.  Quantitative Determination of Cellular Farnesyltransferase Activity: Towards Defining the Minimum Substrate Reactivity for Biologically Relevant Protein Farnesylation , 2014, Chembiochem : a European journal of chemical biology.

[92]  H. Hellinga,et al.  Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design , 2014, Protein science : a publication of the Protein Society.

[93]  Carol L. Williams,et al.  SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers , 2014, Cell cycle.

[94]  Carol L. Williams,et al.  The Chaperone Protein SmgGDS Interacts with Small GTPases Entering the Prenylation Pathway by Recognizing the Last Amino Acid in the CAAX Motif* , 2014, The Journal of Biological Chemistry.

[95]  R. Goody,et al.  Prenylation of RabGTPases, Their Delivery to Membranes, and Rab Recycling , 2014 .

[96]  Ling Li,et al.  Protein Prenylation and Synaptic Plasticity: Implications for Alzheimer’s Disease , 2014, Molecular Neurobiology.

[97]  R. Goody,et al.  Rab GTPase Prenylation Hierarchy and Its Potential Role in Choroideremia Disease , 2013, PloS one.

[98]  J. Nielsen,et al.  Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics* , 2013, Molecular & Cellular Proteomics.

[99]  Carol L. Williams,et al.  The SmgGDS Splice Variant SmgGDS-558 Is a Key Promoter of Tumor Growth and RhoA Signaling in Breast Cancer , 2013, Molecular Cancer Research.

[100]  Li-Lian Yuan,et al.  Farnesyltransferase Haplodeficiency Reduces Neuropathology and Rescues Cognitive Function in a Mouse Model of Alzheimer Disease* , 2013, The Journal of Biological Chemistry.

[101]  F. Eisenhaber,et al.  Prenylation: From bacteria to eukaryotes , 2013, Molecular Biology.

[102]  Carol L. Williams.  A new signaling paradigm to control the prenylation and trafficking of small GTPases , 2013, Cell cycle.

[103]  S. Lamon-Fava.  Statins and lipid metabolism: an update , 2013, Current opinion in lipidology.

[104]  Carol L. Williams,et al.  An Adenosine-Mediated Signaling Pathway Suppresses Prenylation of the GTPase Rap1B and Promotes Cell Scattering , 2013, Science Signaling.

[105]  J. Linden.  Adenosine Promotes Tumor Metastasis , 2013, Science Signaling.

[106]  A. Ridley,et al.  14-3-3 Proteins Interact with a Hybrid Prenyl-Phosphorylation Motif to Inhibit G Proteins , 2013, Cell.

[107]  J. Ochocki,et al.  Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections. , 2013, MedChemComm.

[108]  S. Young,et al.  Targeting Protein Prenylation in Progeria , 2013, Science Translational Medicine.

[109]  Jacqueline Cherfils,et al.  Regulation of small GTPases by GEFs, GAPs, and GDIs. , 2013, Physiological reviews.

[110]  M. Gutkowska,et al.  Structure, regulation and cellular functions of Rab geranylgeranyl transferase and its cellular partner Rab Escort Protein , 2012, Molecular membrane biology.

[111]  A. Kowluru,et al.  Rab-geranylgeranyl transferase regulates glucose-stimulated insulin secretion from pancreatic β cells , 2012, Islets.

[112]  J. Swinnen,et al.  ATP-citrate lyase: a key player in cancer metabolism. , 2012, Cancer research.

[113]  San-yuan Hu,et al.  Expression of farnesyltransferase in primary liver cancer. , 2012, Chinese medical journal.

[114]  Oliver Nussbaumer,et al.  Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents , 2012, Clinical Cancer Research.

[115]  Raman Sharma,et al.  The MEP pathway and the development of inhibitors as potential anti-infective agents , 2012 .

[116]  Shaowu Cheng,et al.  Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer’s Disease , 2012, Molecular Neurobiology.

[117]  M. Bergo,et al.  Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases[S] , 2012, Journal of Lipid Research.

[118]  A. Kowluru,et al.  Nifedipine prevents etoposide-induced caspase-3 activation, prenyl transferase degradation and loss in cell viability in pancreatic β-cells , 2012, Apoptosis.

[119]  R. Hohl,et al.  Geranylgeranyl Diphosphate Synthase: An Emerging Therapeutic Target , 2011, Clinical pharmacology and therapeutics.

[120]  Y. Shao,et al.  GGPPS, a new EGR-1 target gene, reactivates ERK 1/2 signaling through increasing Ras prenylation. , 2011, The American journal of pathology.

[121]  N. Lamango,et al.  Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins. , 2011, European journal of lipid science and technology : EJLST.

[122]  S. Sebti,et al.  Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.

[123]  Ora Schueler-Furman,et al.  Identification of a Novel Class of Farnesylation Targets by Structure-Based Modeling of Binding Specificity , 2011, PLoS Comput. Biol..

[124]  M. Kutner,et al.  Farnesyl transferase expression determines clinical response to the docetaxel‐lonafarnib combination in patients with advanced malignancies , 2011, Cancer.

[125]  E. Piscianz,et al.  Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes , 2011, Apoptosis.

[126]  H. Ogawa,et al.  Polished rice as natural sources of cancer-preventing geranylgeranoic acid , 2011, Journal of clinical biochemistry and nutrition.

[127]  Chaojun Li,et al.  An Early Response Transcription Factor, Egr-1, Enhances Insulin Resistance in Type 2 Diabetes with Chronic Hyperinsulinism* , 2011, The Journal of Biological Chemistry.

[128]  M. Philips.  The perplexing case of the geranylgeranyl transferase-deficient mouse. , 2011, The Journal of clinical investigation.

[129]  M. Bergo,et al.  Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. , 2011, The Journal of clinical investigation.

[130]  Carol L. Williams,et al.  Splice Variants of SmgGDS Control Small GTPase Prenylation and Membrane Localization , 2010, The Journal of Biological Chemistry.

[131]  R. Goody,et al.  Understanding and Exploiting Protein Prenyltransferases , 2010, Chembiochem : a European journal of chemical biology.

[132]  M. Bergo,et al.  Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. , 2010, Human molecular genetics.

[133]  A. Jetten,et al.  Molecular mechanisms involved in farnesol-induced apoptosis. , 2010, Cancer letters.

[134]  H. Ren,et al.  Functional Characterization of the Atypical Integral Membrane Lipid Phosphatase PDP1/PPAPDC2 Identifies a Pathway for Interconversion of Isoprenols and Isoprenoid Phosphates in Mammalian Cells* , 2010, The Journal of Biological Chemistry.

[135]  A. Kowluru,et al.  Protein Farnesylation–Dependent Raf/Extracellular Signal–Related Kinase Signaling Links to Cytoskeletal Remodeling to Facilitate Glucose-Induced Insulin Secretion in Pancreatic β-Cells , 2010, Diabetes.

[136]  James L. Hougland,et al.  Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. , 2010, Journal of molecular biology.

[137]  A. Kowluru,et al.  Glucose activates prenyltransferases in pancreatic islet beta-cells. , 2010, Biochemical and biophysical research communications.

[138]  J. Pelkonen,et al.  The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. , 2009, Bone.

[139]  F. Khuri,et al.  The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner* , 2009, Journal of Biological Chemistry.

[140]  M. Romanelli,et al.  Characterization and functional analysis of cis-acting elements of the human farnesyl diphosphate synthetase (FDPS) gene 5' flanking region. , 2009, Genomics.

[141]  M. Bergo,et al.  Caution! Analyze transcripts from conditional knockout alleles , 2009, Transgenic Research.

[142]  R. Zhao,et al.  Autophagy induced by farnesyltransferase inhibitors in cancer cells , 2008, Cancer biology & therapy.

[143]  R. Goody,et al.  Structures of RabGGTase–substrate/product complexes provide insights into the evolution of protein prenylation , 2008, The EMBO journal.

[144]  K. Tachibana,et al.  Downregulation of Ras C-terminal processing by JNK inhibition. , 2008, Biochemical and Biophysical Research Communications - BBRC.

[145]  F. Dieli,et al.  Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more , 2008 .

[146]  Carol L. Williams,et al.  SmgGDS Regulates Cell Proliferation, Migration, and NF-κB Transcriptional Activity in Non-small Cell Lung Carcinoma* , 2008, Journal of Biological Chemistry.

[147]  D. Andres,et al.  Protein farnesyl transferase target selectivity is dependent upon peptide stimulated product release. , 2007, Biochemistry.

[148]  J. Pereira-Leal,et al.  Multiple domain insertions and losses in the evolution of the Rab prenylation complex , 2007, BMC Evolutionary Biology.

[149]  S. Young,et al.  HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells , 2007, Proceedings of the National Academy of Sciences.

[150]  D. Pérez-Sala.  Protein isoprenylation in biology and disease: general overview and perspectives from studies with genetically engineered animals. , 2007, Frontiers in bioscience : a journal and virtual library.

[151]  Fernanda L. Sirota,et al.  Towards Complete Sets of Farnesylated and Geranylgeranylated Proteins , 2007, PLoS Comput. Biol..

[152]  A. Kowluru,et al.  Dominant-Negative α-Subunit of Farnesyl- and Geranyltransferase Inhibits Glucose-Stimulated, but Not KCl-Stimulated, Insulin Secretion in INS 832/13 Cells , 2007, Diabetes.

[153]  S. Cohen,et al.  microRNA functions. , 2007, Annual review of cell and developmental biology.

[154]  M. Philips,et al.  Thematic review series: Lipid Posttranslational Modifications CAAX modification and membrane targeting of Ras Published, JLR Papers in Press, March 16, 2006. , 2006, Journal of Lipid Research.

[155]  R. Vassar,et al.  Isoprenoids and Alzheimer's disease: A complex relationship , 2006, Neurobiology of Disease.

[156]  L. Beese,et al.  Thematic review series: Lipid Posttranslational Modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I Published, JLR Papers in Press, February 13, 2006. , 2006, Journal of Lipid Research.

[157]  R. Baron,et al.  Thematic review series: Lipid Posttranslational Modifications. Geranylgeranylation of Rab GTPases Published, JLR Papers in Press, January 9, 2006. , 2006, Journal of Lipid Research.

[158]  M. Gelb,et al.  Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation Published, JLR Papers in Press, December 7, 2005. , 2006, Journal of Lipid Research.

[159]  C. Fierke,et al.  Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I. , 2005, Biochemistry.

[160]  C. Fierke,et al.  Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity. , 2005, Biochemistry.

[161]  S. Majumdar,et al.  Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. , 2005, Journal of periodontology.

[162]  F. Eisenhaber,et al.  Refinement and prediction of protein prenylation motifs , 2005, Genome Biology.

[163]  M. Gale,et al.  Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. , 2005, Molecular cell.

[164]  P. Casey,et al.  Post-prenylation-processing enzymes as new targets in oncogenesis , 2005, Nature Reviews Cancer.

[165]  I. Kapetanovic,et al.  Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol. , 2005, Chemico-biological interactions.

[166]  M. Bergo,et al.  Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. , 2005, Molecular biology of the cell.

[167]  M. Barbacid,et al.  Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. , 2005, Cancer cell.

[168]  U. Laufs,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[169]  S. J. McTaggart,et al.  Isoprenylated proteins , 2005, Cellular and Molecular Life Sciences CMLS.

[170]  P. Casey,et al.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. , 2004, Journal of molecular biology.

[171]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[172]  Joseph L Goldstein,et al.  Insig-dependent Ubiquitination and Degradation of Mammalian 3-Hydroxy-3-methylglutaryl-CoA Reductase Stimulated by Sterols and Geranylgeraniol* , 2003, Journal of Biological Chemistry.

[173]  J. Glenn,et al.  Prenylation inhibitors: a novel class of antiviral agents. , 2003, The Journal of antimicrobial chemotherapy.

[174]  Valentina Gelfanova,et al.  Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho , 2003, Science.

[175]  Qiang Wang,et al.  Implication of Geranylgeranyltransferase I in Synapse Formation , 2003, Neuron.

[176]  P. Casey,et al.  High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors* , 2003, Journal of Biological Chemistry.

[177]  Julius Brennecke,et al.  Identification of Drosophila MicroRNA Targets , 2003, PLoS biology.

[178]  Sebastian Maurer-Stroh,et al.  Protein prenyltransferases , 2003, Genome Biology.

[179]  G. De Libero,et al.  Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.

[180]  M. Kay,et al.  A Prenylation Inhibitor Prevents Production of Infectious Hepatitis Delta Virus Particles , 2002, Journal of Virology.

[181]  Stephen B. Long,et al.  Reaction path of protein farnesyltransferase at atomic resolution , 2002, Nature.

[182]  G. Rodan,et al.  Bisphosphonate mechanism of action , 2002, Current molecular medicine.

[183]  C. S. Solomon,et al.  Dominant Negative α-Subunit of FTase Inhibits Effects of Insulin and IGF-I in MCF-7 Cells , 2002 .

[184]  R. Hohl,et al.  Farnesol and geranylgeraniol: Prevention and reversion of lovastatin-induced effects in NIH3T3 cells , 2002, Lipids.

[185]  H. Mo,et al.  Volatile isoprenoid constituents of fruits, vegetables and herbs cumulatively suppress the proliferation of murine B16 melanoma and human HL-60 leukemia cells. , 2002, Cancer letters.

[186]  C. Ng,et al.  Interaction of Farnesylated PRL-2, a Protein-tyrosine Phosphatase, with the β-Subunit of Geranylgeranyltransferase II* , 2001, Journal of Biological Chemistry.

[187]  C. S. Solomon,et al.  Dominant Negative Farnesyltransferase α-Subunit Inhibits Insulin Mitogenic Effects , 2001 .

[188]  J. Olefsky,et al.  Insulin Signals to Prenyltransferases via the Shc Branch of Intracellular Signaling* , 2001, The Journal of Biological Chemistry.

[189]  Junying Yuan,et al.  Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: Cleavage of the common α subunit during apoptosis , 2001, Oncogene.

[190]  F. Tamanoi,et al.  Farnesylated proteins and cell cycle progression , 2001, Journal of cellular biochemistry. Supplement.

[191]  M. Sinensky,et al.  Functional aspects of polyisoprenoid protein substituents: roles in protein-protein interaction and trafficking. , 2000, Biochimica et biophysica acta.

[192]  J. Chappell,et al.  Potentiation of Rho-A-mediated Lysophosphatidic Acid Activity by Hyperinsulinemia* , 2000, The Journal of Biological Chemistry.

[193]  C. Fierke,et al.  Role of metals in the reaction catalyzed by protein farnesyltransferase. , 2000, Biochemistry.

[194]  M. Sinensky,et al.  Recent advances in the study of prenylated proteins. , 2000, Biochimica et biophysica acta.

[195]  F. Bernini,et al.  New insights into the pharmacodynamic and pharmacokinetic properties of statins. , 1999, Pharmacology & therapeutics.

[196]  Y. Le Marchand-Brustel,et al.  Insulin Promotes Phosphorylation and Activation of Geranylgeranyltransferase II , 1999, The Journal of Biological Chemistry.

[197]  M. Goalstone,et al.  Effect of insulin on farnesyltransferase gene transcription and mRNA stability. , 1999, Biochemical and biophysical research communications.

[198]  Y. Matsuzawa,et al.  Effect of farnesyltransferase overexpression on cell growth and transformation , 1999, International journal of cancer.

[199]  S. Michaelis,et al.  Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[200]  D. Accili,et al.  Effect of Insulin on Farnesyltransferase , 1998, The Journal of Biological Chemistry.

[201]  B. Reddy,et al.  Dietary fish oil inhibits the expression of farnesyl protein transferase and colon tumor development in rodents. , 1998, Carcinogenesis.

[202]  E. Swiezewska,et al.  Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. , 1998, Archives of biochemistry and biophysics.

[203]  M. Goalstone,et al.  Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway. , 1997, Endocrinology.

[204]  A. El-Sohemy,et al.  Regulation of mevalonate synthesis in rat mammary glands by dietary n-3 and n-6 polyunsaturated fatty acids. , 1997, Cancer research.

[205]  R. D. Simoni,et al.  Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. , 1997, Archives of biochemistry and biophysics.

[206]  K. Mehta,et al.  p21ras farnesyltransferase α- and β-subunits are phosphorylated in PC-12 cells: TGF-β signaling pathway independent phosphorylation , 1997, Neuroscience Letters.

[207]  P. Casey,et al.  Substrate Binding Is Required for Release of Product from Mammalian Protein Farnesyltransferase* , 1997, The Journal of Biological Chemistry.

[208]  S. Sen,et al.  Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol , 1997, Lipids.

[209]  N. Aboushadi,et al.  Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. , 1997, Biochemical and biophysical research communications.

[210]  Bandaru S. Reddy,et al.  Dietary fat and colon cancer: modulating effect of types and amount of dietary fat on ras-p21 function during promotion and progression stages of colon cancer. , 1997, Cancer research.

[211]  A. Sedman,et al.  Multiple‐dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG‐CoA reductase, in healthy subjects , 1996, Clinical pharmacology and therapeutics.

[212]  M. Goalstone,et al.  Effect of Insulin on Farnesyltransferase Activity in 3T3-L1 Adipocytes* , 1996, The Journal of Biological Chemistry.

[213]  R. Keller,et al.  Squalene synthase inhibition alters metabolism of nonsterols in rat liver. , 1996, Biochimica et biophysica acta.

[214]  J. Massagué,et al.  Interaction of Transforming Growth Factor-β Receptor I with Farnesyl-protein Transferase-α in Yeast and Mammalian Cells* , 1996, The Journal of Biological Chemistry.

[215]  K. Mehta,et al.  α-Subunit of Farnesyltransferase Is Phosphorylatedin Vivo:Effect of Protein Phosphatase-1 on Enzymatic Activity , 1996 .

[216]  R. Dummer,et al.  Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas. , 1996, Biochemical and biophysical research communications.

[217]  Patricia K. Donahoe,et al.  The p21RAS Farnesyltransferase α Subunit in TGF-β and Activin Signaling , 1996, Science.

[218]  K. Miyazono,et al.  Interaction of the Transforming Growth Factor-β Type I Receptor with Farnesyl-protein Transferase-α (*) , 1995, The Journal of Biological Chemistry.

[219]  C. M. Allen,et al.  Changes in protein prenylation and prenyltransferase activity in the rat seminiferous epithelium during early stages of spermatogenesis. , 1995, Biology of reproduction.

[220]  P. Casey,et al.  Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. , 1995, Biochemistry.

[221]  M. Gelb,et al.  Mammalian protein geranylgeranyltransferase-I: substrate specificity, kinetic mechanism, metal requirements, and affinity labeling. , 1995, Biochemistry.

[222]  V. Bansal,et al.  Characterization of 2 Distinct Allyl Pyrophosphatase Activities from Rat-Liver Microsomes , 1994 .

[223]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[224]  C. M. Allen,et al.  Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases. , 1993, Biochemistry.

[225]  C J Marshall,et al.  Protein prenylation: a mediator of protein-protein interactions. , 1993, Science.

[226]  G. Weissmann,et al.  Carboxyl methylation of Ras-related proteins during signal transduction in neutrophils , 1993, Science.

[227]  C. Der,et al.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[228]  W. Schafer,et al.  Protein prenylation: genes, enzymes, targets, and functions. , 1992, Annual review of genetics.

[229]  M. Brown,et al.  Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[230]  W. Epstein,et al.  Quantitation of prenylcysteines by a selective cleavage reaction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[231]  L. Gierasch,et al.  Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[232]  C. Marshall,et al.  A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21 ras to the plasma membrane , 1990, Cell.

[233]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[234]  M. Hanley,et al.  Sticky fingers and CAAX boxes , 1988, Nature.

[235]  R. Schmidt,et al.  Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. , 1984, The Journal of biological chemistry.